MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Consumption of Yerba Mate (Ilex Paraguariensis) in Parkinson’s disease patients from Uruguay

I. Amorín, A. Lescano, N. Ramírez, V. Raggio, R. Buzó (Montevideo, Uruguay)

Meeting: 2016 International Congress

Abstract Number: 472

Keywords: Neuroprotective agents

Session Information

Date: Monday, June 20, 2016

Session Title: Epidemiology

Session Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To know the consumption habits of Yerba Mate in a population of Parkinson’s disease (PD) patients from Uruguay. To compare the consumption habits of Yerba Mate in PD patients from Uruguay with controls from the uruguayan population.

Background: Yerba Mate tea (YM), an infusion made from the leaves of the small tree Ilex paraguariensis, is a very common beverage in Uruguay and other countries of South America. Neuroprotective properties have been attributed to YM probably mediated by its antioxidant activity and antagonism of the A2 adenosin receptors (Milioli, 2006). Recently, an inverse association between YM consumption and PD was reported in an argentinean population and a neuroprotective role was postulated (Gatto, 2015). The present study is the first one in PD patients from Uruguay.

Methods: A customized structured survey was administered to a population of PD patients (n = 50) seen at the Clinics Hospital in Montevideo, Uruguay, since March 2015. The survey addresses the consumption habits of YM (quantity, methods of consumption, time of exposition) as well as others substances postulated as implicated in the development of the disease or as being neuroprotective. The data is compared with a control population (n = 50) consisting of patients without PD or other movement disorders from the same hospital, matched for age and sex.

Results: 82% of the PD patients had consumed YM. A similar frequency of consumption, 84%, was seen in the control group. However, 48% of PD patients reported having abandoned YM consumption at variables times with respect of disease onset.

Conclusions: The study is still in progress and these preliminary results do not find, to date, differences in the consumption of YM between PD patients and a control group in the uruguayan population. During 2016 a more detailed analysis will be carried out and a larger number of patients and controls will be included, which will allow us to draw more accurate conclusions on the potential protective role of YM in PD.

To cite this abstract in AMA style:

I. Amorín, A. Lescano, N. Ramírez, V. Raggio, R. Buzó. Consumption of Yerba Mate (Ilex Paraguariensis) in Parkinson’s disease patients from Uruguay [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/consumption-of-yerba-mate-ilex-paraguariensis-in-parkinsons-disease-patients-from-uruguay/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/consumption-of-yerba-mate-ilex-paraguariensis-in-parkinsons-disease-patients-from-uruguay/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley